Arbutus Biopharma(NASDAQ) ABUS

Arbutus Biopharma Corporation makes medicines to treat chronic hepatitis B. These products help patients by fighting viruses and improving immune health. The company also licenses technology used to deliver vaccines into human cells.

Medicines and Delivery Tools

• Imdusiran: An injectable ribonucleic acid interference (RNAi) therapy designed to reduce viral proteins in patients with chronic hepatitis B.
• AB-101: An oral pill that acts as an immune system activator to help the body respond to liver infections.
• Lipid Nanoparticle (LNP) Technology: Tiny particles made of fat-like molecules used to protect and transport genetic material into cells.
• Royalty Entitlements: Ongoing payments received from partners who use the company’s delivery technology in their own approved drugs.

Winning Patents and Trials

• In March 2026, Arbutus settled legal disputes with Moderna, securing a $950 million noncontingent payment shared with its partner.
• The U.S. Food and Drug Administration granted Fast Track designation to imdusiran in April 2026 to expedite its development and review.
• Arbutus regained full global rights for its lead drug candidate in June 2025 following the conclusion of a partnership with Qilu Pharmaceutical.
• The company reached an agreement with regulators in May 2026 on the design and safety parameters for a mid-stage clinical trial.

Innovation and Intellectual Property

The company possesses a significant collection of patents for lipid nanoparticle technology, which is essential for delivering genetic medicines safely to human cells. Arbutus focuses on combining different therapies to create a functional cure for liver infections rather than lifelong treatments.

Key Financial Performance

• Total revenue was $180.1 million for the six months ended June 30, 2026, up $167.6 million year over year.
• Net income reached $164.6 million during the six-month period ended June 30, 2026.
• Arbutus received $178.4 million on July 8, 2026, as its share of a settlement payment related to patent litigation.
• Cash, cash equivalents, and investments in marketable securities totaled $92.6 million as of June 30, 2026.
• The company’s market capitalization was $922.5 million as of Q1 2026.

Bottom Line

Arbutus has transitioned into a clinical-stage developer with significant cash reserves following major legal settlements. Its progress now depends on the successful advancement of its hepatitis B therapies and the protection of its delivery technology patents.